Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
November 09, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative...
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
August 10, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023...
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
May 11, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
March 23, 2023 07:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill.,...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
October 05, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
September 28, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
August 11, 2022 08:05 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
March 24, 2022 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort ...
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
March 08, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...